Skip to content
‹ Back to IndustriesHealthcare

New Insights on Treating Neurodegeneretive Diseases Could Lead to New Classes of Clinical Trials for Alzheimer’s Disease

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly…

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

·
Share

Free workspace

Turn your Healthcare expertise into content.

Record interviews, organize footage, and write with AI on a free trial of the MarketScale platform for qualifying companies. No demo required, no credit card.

Try it Free

Scientists have been stumped for years on how to awaken stem cells to make new neurons in the human brain; a new study out of the journal Science Advances may have just unlocked critical insight into this neurogenerative puzzle through a roadmap of metabolic pathways. The study, which was conducted on adult and elderly mice, found that a unique gene in their genetically-mutated mice activated dormant neural stem cells, in effect generating new neurons in the brain. This discovery to awaken stem cells may lead to new clinical trials for treating people with neurodegenerative diseases, including an estimated 6.5 million Americans ages 65 and older who are living with Alzheimer’s in 2022.

With the increasing number of people developing these diseases, will there be many more discoveries down the road? Overall, clinical trials for Alzheimer’s disease medications are giving new options to patients.

“Alzheimer’s research is getting to a place where cancer research was maybe 30, 40 years ago,” says Anton Porsteinsson, MD, director of the Alzheimer’s Disease Care, Research and Education Program at the University of Rochester Medical Center in New York, as quoted in the Association of American Medical Colleges News. “I think we’re at a point where we’re going to see a logarithmic increase in discovery.”

Dr. Dung Trinh, MD, Chief Medical Officer of the Healthy Brain Clinic, which provides individualized plans for brain health with coaching and support including memory testing and brain health exams, gives his perspective on this new research and helps track the implications of this research for neurobiologists and for patients with neurodegenerative diseases.

Dung’s Thoughts

“Neural degeneration, otherwise known as the loss of brain cells, is a very common thread among pretty much all the neural degenerative diseases we have in the brain that includes Alzheimer’s disease and other dementias such as vascular dementia. It includes multiple sclerosis and Parkinson’s disease. The one underlying thread is the loss of brain cells, otherwise known as neurodegeneration.

So, this research actually is very exciting. We have not found a strategy to reproduce successfully more brain cells that have been less with these neurodegenerative diseases. And the best we’ve had so far is to hopefully try to slow down neurodegeneration, but the ability to create more brain cells, especially from stem cells that have been inactive in the brain, is a very exciting new revelation.

And this will lead to new classes of clinical trials and studies that will revolutionize this field. The field of neurodegeneration unfortunately have not caught up as far as finding new treatments and finding new medications due to the fact that we have not been able to successfully create or find a way to make new brain cells consistently. ”

Article written by Sonya Young.

Your experts belong here

Every story in MarketScale Healthcare starts with a company putting its clinicians, service-line leaders, and field engineers on the record. Buyers are already reading this topic. The only question is whose experts they find.

Service-line buyers vet vendors quietly, and your clinicians become the proof they find while doing it.

Book DemoSee how it works15 minutes, straight to a calendar.
B2B Weekly

The week in Healthcare, and sixteen other industries, every Monday.

Ten stories, one-line takes, five minutes. Free.

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. Explore how your experts, customers, and partners can become useful content for buyers and AI search.

Free Trial

You just read one Healthcare expert. Your company is full of them.

This article was produced through MarketScale. The same platform turns your clinicians, service-line leaders, and field engineers into the articles, video, and social content Healthcare buyers are searching for. Start a free trial and see it with your own people. For qualifying companies, no credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What your free trial includes

Hands-on access to the MarketScale platform
Media requests to your crowd, remote recording, AI writing tools
No demo required. No credit card.
For qualifying companies. Company confirmation required.

More Healthcare Insights

Censis now reads da Vinci QR codes to count robotic arm uses

Censis now reads da Vinci QR codes to count robotic arm uses

Censis Technologies told CtUC 2026 attendees that CensiTrac has read the QR code on da Vinci arms since April, so robotic arms carry use counts without a second mark. The session built a business case for CensiTrac Advanced around marked assembly, clinic inventory ownership and par levels, with a 2021 BMJ Quality & Safety study putting missing instruments at 17.6% of assembly defects.

  • 01CensiTrac has counted da Vinci arm uses from the code that already comes on each arm since April, with no laser or etch added.
  • 02Hospitals told Censis they want clinic inventory tracking mainly to prove sterile processing did not lose the instruments.
  • 03Missing instruments were 17.6% of assembly tray defects at a 700-bed hospital in a 2021 BMJ Quality & Safety study, a problem the presenter tied to marked assembly.

Nov 5, 2026

AdvaMed approves voluntary data access best practices for medtech companies and health systems

AdvaMed approves voluntary data access best practices for medtech companies and health systems

AdvaMed's Digital Health Tech board approved voluntary Data Access Principles & Best Practices, announced October 28, setting four principles for how medtech companies and U.S. health systems share data.

  • 01The framework covers data vendors need to implement, monitor and improve technology, with expectations for transparency, stewardship and de-identification.
  • 02Watch for the first RFPs, security questionnaires or data use agreements that cite the principles by name; a voluntary document gains weight only when buyers adopt it.

Nov 5, 2026

Nearly 500 hospitals track shortage-affected segments via RFID

Nearly 500 hospitals track shortage-affected segments via RFID

According to Bluesight, nearly 500 hospitals track almost 4,000 shortage-affected medication segments in their RFID systems. Checks of dispensing cabinets have been missing that RFID-tracked supply. Gilman argues that bringing RFID data in next to cabinet data gives more complete usage rates and days-on-hand calculations, though the gain could depend on whether systems connect at the transaction level.

  • 01During a shortage, a count that stops at the dispensing cabinet can misstate both stock on hand and usage rate, creating a false sense of urgency and wasteful emergency purchases.
  • 02RFID is no longer limited to kit and tray management: nearly 500 hospitals already track almost 4,000 shortage-affected medication segments in their RFID systems.
  • 03For operators weighing a merged feed, the key question could be whether RFID usage flows into the days-on-hand calculation at the transaction level or sits beside cabinet data as a static count.

Nov 4, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a Demo

Or call us. No forms required. We pick up. 214-945-2512